A share price of Neurogene Inc [NGNE] is currently trading at $20.07, down -0.05%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NGNE shares have gain 4.86% over the last week, with a monthly amount drifted -1.81%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurogene Inc [NASDAQ: NGNE] stock has seen the most recent analyst activity on June 17, 2025, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $50. Previously, Robert W. Baird downgraded its rating to Neutral on May 16, 2025, and kept the price target unchanged to $24. On June 27, 2024, BMO Capital Markets initiated with an Outperform rating and assigned a price target of $65 on the stock. Robert W. Baird started tracking the stock assigning an Outperform rating and suggested a price target of $54 on June 11, 2024. Leerink Partners initiated its recommendation with an Outperform and recommended $46 as its price target on April 29, 2024. William Blair started tracking with an Outperform rating for this stock on March 21, 2024, and assigned it a price target of $61. In a note dated January 08, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $45 on this stock.
Neurogene Inc experienced fluctuations in its stock price throughout the past year between $6.88 and $37.27. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. Neurogene Inc [NASDAQ: NGNE] shares were valued at $20.07 at the most recent close of the market. An investor can expect a potential return of 124.22% based on the average NGNE price forecast.
Analyzing the NGNE fundamentals
Gross Profit Margin for this corporation currently stands at 2.56% with Operating Profit Margin at 105.2%, Pretax Profit Margin comes in at 92.03%, and Net Profit Margin reading is 92.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.3 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.76 points at the first support level, and at 19.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.32, and for the 2nd resistance point, it is at 20.57.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Neurogene Inc [NASDAQ:NGNE] is 18.37. Also, the Quick Ratio is 18.37, while the Cash Ratio stands at 4.83.
Transactions by insiders
Recent insider trading involved Cobb Stuart, Chief Scientific Officer, that happened on May 14 ’25 when 6797.0 shares were sold. Officer, STUART COBB completed a deal on May 14 ’25 to buy 6797.0 shares. Meanwhile, President and CFO Cvijic Christine Mikail sold 4501.0 shares on Mar 13 ’25.
